Printer Friendly

Selvita names Dr Setareh Shamsili as chief medical officer.

M2 EQUITYBITES-July 25, 2019-Selvita names Dr Setareh Shamsili as chief medical officer

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Drug discovery company Selvita SA (WSE:SLV) reported on Wednesday the addition of Setareh Shamsili, MD, PhD, as its chief medical officer.

Most recently, Dr Shamsili has served as interim chief medical officer at AxImmune, a US-based immuno-oncology company.

Previously, Dr Shamsili was chief medical officer of Merus NV, where she brought the initial two candidates to the clinic for development in acute myeloid leukemia and the treatment of solid tumours.

Earlier in her career, Dr Shamsili served as the global medical leader oncology at Astellas Pharma Global Development.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 25, 2019
Words:120
Previous Article:RaySearch extends collaboration with Mevion to support advanced HYPERSCAN treatment planning capabilities.
Next Article:Health Catalyst prices IPO at USD26.00 per share.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |